A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Recruiting now · Phase 4
Conditions studied: Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic
In brief
This study will evaluate the long-term safety of pirtobrutinib in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study is open to those who completed J2N-MC-JZNN/LOXO-BTK-20020 (NCT 04666038) for continued access to the study intervention or continued follow-up visits. Treatment will be given every 4 weeks and this study is expected to last about 5 years.
Key facts
- Study ID
- NCT07218341
- Run by
- Eli Lilly and Company
- People needed
- 150
- Starts
- 2026-03-09
- Expected to finish
- 2032-12-01
- Last updated by the study team
- 2026-08-06
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Are actively participating in study J2N-MC-JZNN/LOXO-BTK-20020
You may not qualify if…
- This is not applicable to this study
Where it is running
- Hematology Hospital of the Chinese Academy of Medical Sciences — Tianjin, China (enrolling)
- Tokai University Hospital — Isehara, Japan (enrolling)
- Memorial Sloan-Kettering Cancer Center (MSKCC) - New York — New York, New York, United States (enrolling)
- Cancer Specialists, LLC — Jacksonville, Florida, United States (enrolling)
- St James's University Hospital — Leeds, United Kingdom (enrolling)
- Mitchell Cancer Institute — Mobile, Alabama, United States (enrolling)
- US Oncology - Texas Oncology — Kyle, Texas, United States
- The Alfred Hospital — Melbourne, Australia
- LKH - Universitätsklinikum der PMU Salzburg — Salzburg, Austria
- AZ Delta — Roeselare, Belgium
- Princess Margaret Cancer Centre - University Health Network — Toronto, Canada
- Xuanwu Hospital Capital Medical University — Beijing, China
- Hunan Cancer Hospital — Changsha, China
- Sun Yat-sen University Cancer Center — Guangdong, China
- Nanfang Hospital of Southern Medical University — Guangzhou, China
- Gansu Provincial Cancer Hospital — Lanzhou, China
- The First Affiliated Hospital of Nanchang University — Nanchang, China
- Fudan University Shanghai Cancer Center — Shanghai, China
- Taizhou Hospital of Zhejiang Province — Taizhou, China
- Tianjin Medical University Cancer Institute & Hospital — Tianjin, China
- Affiliated Cancer Hospital of Xinjiang Medical University — Ürümqi, China
- The Affiliated Hospital of Xuzhou Medical College — Xuzhou, China
- Henan Cancer Hospital — Zhengzhou, China
- University Hospital Center Zagreb — Zagreb, Croatia
- Fakultni nemocnice Hradec Kralove — Hradec Králové, Czechia
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.